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Short Communication
Immunoreactive pattern of Staphylococcus
epidermidis biofilm against human whole
saliva
Saliva is essential to interact with microorganisms in the oral cavity. Therefore, the inter-
est in saliva antimicrobial properties is on the rise. Here, we used an immunoproteomic
approach, based on protein separation of Staphylococcus epidermidis biofilms by 2DE, fol-
lowed by Western-blotting, to compare human serum and saliva reactivity profile. A total
of 17 proteins were identified by MALDI-TOF/TOF. Serum and saliva presented a distinct
pattern of immunoreactive proteins. Our results suggest that saliva seems to have higher
propensity to react against S. epidermidis proteins with oxidoreductase activity and proteins
involved with L-serine metabolic processes. We show that saliva was a powerful tool for
the identification of potential S. epidermidis biofilms proteins.
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Despite enormous efforts have been made in the search of
new diagnostic techniques and new therapeutic strategies,
infections caused by bacteria still remain high. Biofilms are
often defined as “a structured community of bacterial cells
enclosed in a self-produced polymeric matrix and adherent to
an inert or living surface [1].” The extracellular matrix, where
biofilm cells are embedded, contributes to bacteria survival
in a hostile environment [2]. Thus, biofilms have a higher ca-
pacity than planktonic cells to tolerate immune response [3].
Moreover, the physiological heterogeneity and evasion to the
host immune system also contribute to a hardly effective
elimination of the microorganism [4]. Biofilm-associated in-
fectionsmay represent 80%of the chronic bacterial infections
diagnosed [5]. Staphylococcus epidermidis is a commensal col-
onizer of skin and mucosae [6]. Nevertheless, S. epidermidis
biofilms are among the major responsible for chronic in-
fections since frequently adhere to indwelling medical de-
vice [7]. Nowadays, in order to find amore effective treatment
to biofilms, there is an increased interest in identification
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and development of antimicrobial peptides. For example,
a promising peptide was recently developed and presented
antimicrobial efficacy over biofilms, including Staphylococ-
cus aureus biofilms, since it targets (p)ppGpp, a nucleotide
which is a signal of a stress condition, such as nutritional
stress [8].
Due to its involvement in protection to microbial colo-
nization [9], the interest in the saliva antimicrobial proper-
ties has been increasing [10]. Saliva is a plasma ultrafiltrate
fluid, which includes specific proteins produced by salivary
glands [11]. It is estimated that approximately 20% of total
salivary proteins are also seen in plasma [12]. Immune mark-
ers of systemic infections, such as antigens, antibodies, and
nucleic acids of infecting pathogens, are suspected to enter
saliva from the blood through absorption and subsequent
secretion by the salivary glands [13]. Additionally, salivary
proteins are crucial to interact with oral cavity microorgan-
isms [14]. The purpose of this work was to assess the saliva
potential against S. epidermidis biofilm proteins, comparing
the immunoproteomic profile of human whole saliva and
human serum.
Whole proteome was obtained from S. epidermidis
biofilms grown in a glucose-enriched medium, as described
in [15]. To obtain whole proteome, biofilms were directly
scrapped and resuspended with detergent extraction buffer,
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Figure 1. Immunoblotting profile of whole proteins of S. epidermidis biofilms using whole human saliva (A) and human serum (B) as
probes. Protein spot identification is mentioned in Table 1.
Table 1. Immunoreactive proteins identified by 2DE-MALDI-TOF/TOF
Spot Protein Acession
number
Protein name MW
(kDa)
pI Function PSORTb
localization
Cell
localization
1 SsaA Q5HLV2 Staphylococcal secretory
antigen SsaA
27.91 8.4 Not known; immunogenic
protein expressed
during sepsis and
particularly during
episodes of infective
endocarditis
Extracellular Extracellular
2 Fda Q5HL21 Fructose-bisphosphate
aldolase class 1
32.99 4.89 Glycolytic enzyme that
catalyzes D-fructose
1,6-bisphosphate into
glycerone phosphate
and D-glyceraldehyde
3-phosphate
Unknown Cytoplasmic
3 CysK Q5HRP1 Cysteine synthase 33.15 5.18 Catalyzes the reaction that
led to acetate formation
Cytoplasmic Cytoplasmic
4 FusA Q5HRK5 Elongation factor G 76.88 4.8 This protein promotes the
GTP-dependent
translocation of the
nascent protein chain
from the A-site to the
P-site of the ribosome
Cytoplasmic Cytoplasmic
5 PfkA Q5HNK6 6-Phosphofructokinase 34.88 5.34 Catalyzes the reaction of
D-fructose 6-phosphate
into D-fructose
1,6-bisphosphate
Cytoplasmic Cytoplasmic
6 GlyA Q5HMB0 Serine hydroxymethyl-
transferase
45.24 5.73 Catalyzes the reversible
interconversion of
serine and glycine with
tetrahydrofolate serving
as the one-carbon
carrier
Cytoplasmic Cytoplasmic
7 Gap Q5HQV4 Glyceraldehyde-3-
phosphate
dehydrogenase 1
36.19 4.83 Catalyzes the conversion
of glyceraldehyde
3-phosphate to D-
glycerate
1,3-bisphosphate
Cytoplasmic Cytoplasmic
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Table 1. Continued
Spot Protein Acession
number
Protein name MW
(KDa)
pI Function PSORTb
localization
Cello
localization
8 CodY Q5HPT7 GTP-sensing
transcriptional
pleiotropic repressor
CodY
28.75 5.61 It is a GTP-binding protein
that senses the
intracellular GTP
concentration as an
indicator of nutritional
limitations. At low GTP
concentration it no
longer binds GTP and
stop to act as a
transcriptional repressor
Cytoplasmic Cytoplasmic
9 SERP0527 Q5HQM1 NADH dehydrogenase-like
protein SERP0527
44.18 5.80 It catalyzes the transfer of
a pair of electrons from
NADH
Cytoplasmic
membrane
Cytoplasmic
10 AhpC Q5HRY1 Alkyl hydroperoxide
reductase subunit C
21.0 4.58 Directly reduces organic
hydroperoxides in its
reduced dithiol form
Cytoplasmic Cytoplasmic
11 Pgk Q5HQV3 Phosphoglycerate kinase 42.74 4.76 Catalyzes the transference
of a phosphate group
from
3-phospho-D-glycerate
to ADP
Cytoplasmic Cytoplasmic
12 RpsA Q5HP69 30S ribosomal protein S1 43.37 4.46 Binds mRNA, thus
facilitating recognition
of the initiation point. It
is needed to translate
mRNA with a short
Shine-Dalgarno (SD)
purine-rich sequence
Cytoplasmic Cytoplasmic
13 GpmA Q5HLI0 2,3-Bisphosphoglycerate-
dependent
phosphoglycerate
mutase
26.7 6.46 Catalyzes the
interconversion of
2-phosphoglycerate and
3-phosphoglycerate
Cytoplasmic Cytoplasmic
14 Tuf Q5HRK4 Elongation factor Tu 43.16 4.7 This protein promotes the
GTP-dependent binding
of aminoacyl-tRNA to
the A-site of ribosomes
during protein
biosynthesis
Cytoplasmic Cytoplasmic
15 TpiA Q5HQV2 Triosephosphate
isomerase
27.37 4.9 Catalyzes the
interconversion of
D-glyceraldehyde
3-phosphate and
glycerone phosphate
Cytoplasmic Cytoplasmic
16 Asp23 Q5HM47 Alkaline shock protein 23 19 4.92 May play a key role in
alkaline pH tolerance
Unknown Cytoplasmic
17 GpmI Q5HQV1 2,3-Bisphosphoglycerate-
independent
phosphoglycerate
mutase
56.36 4.8 Catalyzes the
interconversion of
2-phosphoglycerate and
3-phosphoglycerate
Cytoplasmic Cytoplasmic
25 mM Tris-HCl (Pharmacia Biotech, Uppsala, Sweden)
(pH 7.2), 10 mM CHAPS (Sigma-Aldrich, St. Louis, MO),
0.5MNaCl (VWR, Radnor, PA), 5% glycerol (Sigma-Aldrich),
and 1 mM PMSF (Sigma-Aldrich). Cells were disrupted by
mechanical lysis using a FastPrep R© (Thermo Fisher Sci-
entific, Waltham, MA) cell disruptor (three cycles of 30 sec
and 6.5 m/s). After lysis, cell debris was removed by cen-
trifugation (15 000 × g for 15 min at 4°C) and proteins were
precipitated with 20% of TCA-cold acetone (Sigma-Aldrich)
and quantified using the RC-DC assay (Bio-Rad, Hercules,
CA). Proteins were separated by 2D electrophoresis, as
described in [16]. Then, proteins were transferred to a nitro-
cellulose membrane in transfer buffer. Immunoblotting was
performed with human saliva or human serum. Sec-
ondary antibody against Human IgG was used (A0170,
Sigma-Aldrich). Immunoreactive spots were detected by
enhanced ECL (Amersham Pharmacia Biotech, UK). Finally,
immunoreactive proteins were excised from 2DE stained
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Figure 2. Data analysis using
STRING tool. Themost repre-
sentative GO terms of biolog-
ical processes (A), molecular
functions (B), andKEGGpath-
ways (C) of immunoreactive
proteins.
with colloidal Coomassie and in-gel protein digestion was
performed as described in [15,17]. Proteins were identified by
MALDI-TOF/TOF, as described in [17]. Gene Ontology [18]
and KEGG pathways [19] were determined by using STRING
tool [20]. Biological samples were collected from healthy
volunteers after written informed consent (approved by
the Ethics Committee of Instituto Cieˆncias Biome´dicas
Abel Salazar (document number 081/2014)). Complete
Material and methods section may be found in Supporting
Information.
It is known that human saliva and serum have different
contact with Staphylococcus spp. Among the highmicrobiome
diversity, oral mucosa is frequently colonized by S. aureus,
which is found in 4–64% of healthy subject’s plaque [21].
Also S. epidermidis was found as a colonizer of subgingival
plaque in periodontally healthy people [22]. Later, Negrini
et al. showed that S. epidermidis biofilms were able to stim-
ulate inflammatory response of salivary epithelial cells [23].
Not surprisingly, the immunoreactive profile obtained by
serum and saliva was distinct (Fig. 1). Nevertheless, several
proteins were reactive with both biological fluids. Sera have
been used in immunoproteomics to identify S. epidermidis
immunogenic proteins [24]. However, reactive pattern may
diverse among sera samples, since it is strongly dependent
on immune response of donors or previous exposure
to bacteria [25–29]. Nevertheless, here, we identified a
total of 17 S. epidermidis proteins (Table 1), wherein six
proteins were found reactive only to saliva and nine proteins
were found reactive to saliva and serum. Gene Ontology
analysis (Fig. 2 B) showed that these proteins were mainly
involved in small molecule metabolic process (GO:0044281)
and catabolic processes (GO:0009056). Their main molecular
functions were catalytic activity (GO:0003824) and ion
binding (GO:0043167). Similarly, the main representative
KEGG pathways were microbial metabolism in diverse
environments (ser01120), and metabolic pathways, such
as biosynthesis of secondary metabolites (ser01110) and
glycolysis/gluconeogenesis (ser00010). More than a half of
the identified proteins were both reactive to saliva and serum.
Amongst them, there is a well-known immunogenic protein,
SsaA [30]. CysK, FusA, GlyA, Gap, SERP0527, and AhpC pro-
teins seem to be more reactive to human saliva than human
serum (Fig. 1). Half of them present oxidoreductase activity
(Gap, AhpC, and SERP0527 proteins). Additionally, L-serine
metabolic process (including GlyA and CysK proteins) was
a biological process found only in saliva experiment. It is
known that the amino acid L-serine plays a role in cellular
proliferation [31]. This result may suggest that saliva contains
factors with activity against growing bacteria. Indeed, saliva
encompasses a large panel of antimicrobial peptides to
C© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim www.electrophoresis-journal.com
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balance the bacteria growth in oral cavity, which may be
determinant to establish homeostasis [10]. Despite the saliva
proteome is constituted of more than 2400 salivary proteins,
there is interindividual variability in the composition of saliva
proteins [32]. Interestingly, around 21% of proteins found
in human saliva are associated with immunity [33]. Heo and
colleagues exposed S. aureus biofilm to human saliva in order
to identify salivary protein binding [34]. Their main aim was
to decipher the mechanism by which the microorganism
can colonize the oral cavity. They found that a limited
number of salivary proteins, mainly involved in specific or
innate immune defense, interact and influence S. aureus
metabolism, contributing to host–pathogen interplay [34].
Conversely, Staphylococcal protein A (SpA) was the main
responsible for binding salivary immunoglobulins. Further-
more, Trindade et al. showed the potential antimicrobial
activity of different saliva peptides isolated from mammals
on S. aureus exponential planktonic cells [35].
To the best of our knowledge, the present study repre-
sents, in general, the first attempt to use saliva as a probe
for immunoblotting against bacterial proteins. Our results
suggest that human saliva seems to be more reactive to pro-
teins from S. epidermidis biofilm with oxidoreductase activity.
Despite high interindividual variability, it would be of major
importance to identify which salivary peptides are binding to
those proteins and assess their influence over biofilms.
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